Abstract: An object of the present invention is to elucidate the onset mechanism of MSA through specification of a causative gene of it and further, to find a treatment method of it. The present invention provides a method for testing a multiple system atrophy risk of a test subject including a step of detecting a variant that deteriorates the biosynthesis of coenzyme Q10 in a sample collected from the test subject. Examples of the variant that deteriorates the biosynthesis of coenzyme Q10 include variants that suppress the expression or function of coenzyme Q2.
Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.
Type:
Application
Filed:
April 14, 2014
Publication date:
March 10, 2016
Applicant:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Abstract: Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof.
Type:
Application
Filed:
November 19, 2015
Publication date:
March 10, 2016
Applicant:
Cimas Limited
Inventors:
Shalva MARDI, Rosa MARDI, Gymsher MARDI, Laura MARDI, Shimon SLAVIN
Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Type:
Application
Filed:
November 16, 2015
Publication date:
March 10, 2016
Inventors:
Aaron DODD, Felix MEISER, Marck NORRET, Adrian RUSSELL, H William BOSCH
Abstract: This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis.
Abstract: Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.
Abstract: The present invention relates to a composition for preventing or treating renal fibrosis comprising dimethylfumarate (DMF) as an active ingredient. The DMF according to the present invention has an excellent effect of reducing renal fibrosis by activating Nrf2 to inhibit TGF-?/Smad signaling, and thus is useful for preventing or treating renal fibrosis.
Type:
Application
Filed:
February 20, 2013
Publication date:
March 10, 2016
Inventors:
In Kyu Lee, Keun Gyu Park, Chang Joo Oh
Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
Type:
Application
Filed:
September 21, 2015
Publication date:
March 10, 2016
Applicant:
UNIVERSITY OF SOUTH FLORIDA
Inventors:
Dominic Paul D'Agostino, Patrick Arnold, Shannon Kesl
Abstract: The present invention relates to an adhesion preventing agent comprising an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, AA: AA denotes a single bond or double bond, and R denotes a hydrophilic group having two or more hydroxyl groups.
Abstract: The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits ?-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity.
Type:
Application
Filed:
November 5, 2015
Publication date:
March 10, 2016
Applicant:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Tae-Sook Jeong, Ho-Yong Park, Ki Hun Park
Abstract: Rhodamine dye is delivered to regions of a lung having heterogeneous alveolar flooding by alveolar liquid, thereby lowering the surface tension of the alveolar liquid so as to lessen ventilation injury directly and, by promoting equitable redistribution of the alveolar liquid among the alveoli of the lung, indirectly. The rhodamine dye is delivered with an albumin and/or an exogenous surfactant. Exemplary rhodamine dyes include sulforhodamine B and rhodamine WT.
Type:
Application
Filed:
November 13, 2015
Publication date:
March 10, 2016
Applicant:
THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY
Abstract: The present invention relates to a pharmaceutical composition for the prophylaxis and/or treatment of a melanoma and a precursor thereof as well as a skin and mucosa metastasis and uses and methods associated therewith.
Abstract: The invention relates to methods of inducing insulin production in non-beta-cells or converting non-beta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and methods of predicting the susceptibility of a diabetic subject to a treatment.
Type:
Application
Filed:
March 14, 2014
Publication date:
March 10, 2016
Applicant:
UNIVERSITE DE GENEVE
Inventors:
Pedro HERRERA, Fabrizio THOREL, Simona CHERA
Abstract: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.
Type:
Application
Filed:
November 18, 2015
Publication date:
March 10, 2016
Applicant:
Creative Medical Health Inc.
Inventors:
Tom E. Ichim, Neil H. Riordan, Fabio Solano Salazar
Abstract: A method of treating hyperhidrosis in a mammalian subject comprising: a) providing a composition comprising a pharmaceutically acceptable vehicle and from about 1.0% to about 25% of a compound having the formula: and b) topically administering the composition to skin of an area of a mammalian subject suffering from hyperhidosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least about 25% for at least about six (6) hours.
Abstract: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.
Abstract: The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
Type:
Application
Filed:
April 6, 2015
Publication date:
March 10, 2016
Inventors:
Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
Abstract: Formulations and methods of providing an orally-active anti-metabolic disease Fixed Dose Combinations (FDC) for use as personalized medicine to treat different components of the Metabolic Syndrome or Insulin resistance syndrome such as Type II diabetes, Hypertension, Hyperlipidemia and Obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of NSAIDS in general and selective Cox-2 inhibitors in particular and one or more anti-T2DM or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed.
Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
Type:
Application
Filed:
September 4, 2015
Publication date:
March 10, 2016
Inventors:
Helen S. PENTIKIS, David PALLING, Carol J. BRAUN
Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Type:
Application
Filed:
November 5, 2015
Publication date:
March 10, 2016
Inventors:
Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.
Type:
Application
Filed:
November 16, 2015
Publication date:
March 10, 2016
Applicant:
HOSPIRA, INC.
Inventors:
Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis Stalker, Edward Koo
Abstract: A method for inducing an activity of an Nrf2 in a cell is disclosed. The method includes administering to the cell a therapeutically effective amount of an ergothioneine that induces an expression of the Nrf2, wherein the cell is a normal cell or a damaged cell resulting from an exposure to an ultraviolet radiation (UVR).
Abstract: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
Type:
Application
Filed:
November 19, 2015
Publication date:
March 10, 2016
Inventors:
Mohammed I. Dibas, John E. Donello, Daniel W. Gil
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract: Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Type:
Application
Filed:
November 17, 2015
Publication date:
March 10, 2016
Inventors:
Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
Abstract: Described herein is an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Three compounds with estradiol inhibitory capability (letrozole, anastrozole and fenbendazole) were tested in vitro using bovine granulosa cell culture. Letrozole was found to be the most efficient and potent inhibitor. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. Samples were collected over a 24 h period. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. In an in vivo study in cattle, 3 different intravaginal devices containing 3 g of letrozole were tested: Wax (with 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine, DOPE) +gel coat (n=2), Wax+gel coat (n=4) and Wax (n=4).
Type:
Application
Filed:
April 17, 2014
Publication date:
March 10, 2016
Inventors:
Gregg Patrick ADAMS, Maria Jimena YAPURA, Roger A. PIERSON, Ildiko BADEA
Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
Type:
Application
Filed:
September 10, 2015
Publication date:
March 10, 2016
Inventors:
Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
Abstract: The invention relates to a pharmaceutical combination comprising the compound of formula I or pharmaceutically acceptable salts thereof in combination with at least one second therapeutic agent 2. The pharmaceutical combination of the invention is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Type:
Application
Filed:
November 18, 2015
Publication date:
March 10, 2016
Inventors:
Bradford S. HAMILTON, Thomas RAUCH, Manami TSUTSUMI
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR in therapeutic responsiveness to rapamycin analogs.
Type:
Application
Filed:
September 14, 2015
Publication date:
March 10, 2016
Inventors:
James J. Hsieh, Michael Berger, Robert Motzer, Martin H. Voss, Ari A. Hakimi, Can Pham, Emily Cheng, Rose Brannon, Jianing Xu
Abstract: Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.
Type:
Application
Filed:
November 12, 2015
Publication date:
March 10, 2016
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Gabriel Pardo, Gustavo Adolfo Suarez Zambrano, Cecilie Fjeldstad
Abstract: A compound having the following formula (I): for its use as a drug in the treatment and/or the prevention of depression, with the proviso that said compound is not for use as drug in the treatment of women depressive state associated with premenstrual dysphoric disorder.
Abstract: Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment.
Type:
Application
Filed:
September 8, 2015
Publication date:
March 10, 2016
Inventors:
Andrew R. Blight, Anthony O. Caggiano, Tom J. Parry, Jennifer F. Iaci
Abstract: The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea.
Type:
Application
Filed:
November 19, 2015
Publication date:
March 10, 2016
Applicant:
NeuroHealing Pharmaceuticals, Inc.
Inventors:
Marcelo Merello, Neal M. Farber, Eyal S. Ron
Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
Type:
Application
Filed:
November 16, 2015
Publication date:
March 10, 2016
Applicant:
SANIONA APS
Inventors:
Janus Schreiber LARSEN, Magnus GUSTAFSSON, Carsten JESSEN
Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
Type:
Application
Filed:
March 19, 2013
Publication date:
March 10, 2016
Inventors:
Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
Abstract: Methods and compositions are provided for modifying the eating behavior of an individual. The compositions provide an oral stimulatory effect such as tingling, cooling, and/or warming. Consumption of the compositions after eating a desired amount of food may habituate the individual to ending a meal and serve to cue cessation of eating, assisting the individual with ending a meal at a time point before a signal of satiety has reached the brain. Consumption of the composition in lieu of snacking between meals may assist the individual with avoiding consumption of snacks.
Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
Type:
Application
Filed:
January 23, 2015
Publication date:
March 10, 2016
Inventors:
Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
Abstract: The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g.
Type:
Application
Filed:
March 17, 2014
Publication date:
March 10, 2016
Applicant:
University of Florida Research Foundation, Inc.
Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Type:
Application
Filed:
April 10, 2014
Publication date:
March 10, 2016
Inventors:
Christopher Carreras, Dominique Charmot, Jeffrey W Jacobs, Eric Labonte, Jason G. Lewis
Abstract: Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.
Abstract: Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks.